araag2/HINT huggingface dataset:
Clinical trial NCT01074268 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin detemir, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 12 months

          -  Current treatment with any basal bolus insulin for at least 12 months

          -  HbA1c below or equal to 10.0%

          -  Body Mass Index (BMI) below or equal to 35.0 kg/m^2

          -  For Japan only: Minimum age is 20 years

          -  For the extension trial only: Completed the six-month treatment period in trial
             NN1250-3585 (NCT01074268)

        Exclusion Criteria:

          -  Use of any other antidiabetic drug than insulin within the last 3 months

          -  Cardiovascular disease within the last 6 months

          -  Uncontrolled treated/untreated severe hypertension

          -  Recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for
             diabetic ketoacidosis during the previous 6 months

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures

          -  Cancer and medical history of cancer
Clinical trial NCT00087737 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: dvs-233 sr, venlafaxine er
SMILES: COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients.

          -  Sexually active individuals participating in the study must use a medically acceptable
             form of contraception during the study and for at least 15 days after the last dose of
             test article

          -  Subjects must have a primary diagnosis of major depressive disorder

        Exclusion Criteria:

          -  Treatment with DVS-233 SR at any time in the past

          -  Treatment with venlafaxine (immediate release [IR] or ER) within 90 days of study day
             1

          -  Known hypersensitivity to venlafaxine (IR or ER)
Clinical trial NCT00707304 (phase 3, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: talactoferrin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed stage IIIB or IV NSCLC

          -  Failed at least 2 prior systemic anti-cancer regimens for advanced or metastatic NSCLC

          -  At least one target lesion that is unirradiated and measurable by RECIST

          -  Adequate hematologic, renal and hepatic function

          -  ECOG 0, 1, or 2

          -  Able to understand and sign an Informed Consent

        Exclusion Criteria:

          -  Presence of brain metastases, unless the patient received brain irradiation, including
             adequate stereotactic radiosurgery, at least 4 weeks prior to randomization, and is
             stable, asymptomatic, and off steroids for at least 3 weeks prior to randomization

          -  Any gastrointestinal tract disease or other medical condition resulting in the
             inability to take oral medications

          -  History of other malignancies except: (i) adequately treated basal or squamous cell
             carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine
             cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other
             curatively treated solid tumor with no evidence of disease for ≥ 5 years

          -  Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart
             failure

          -  Serious active infection

          -  Psychiatric illness/ social situations that would limit study compliance

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 4 weeks prior to
             randomization or previous radiotherapy to the target lesion sites (the sites that are
             to be followed for determination of a response)

          -  Known HIV positive or on active anti-retroviral therapy

          -  Known Hepatitis B surface antigen positive or hepatitis C positive

          -  Receipt of any investigational medication within 4 weeks prior to randomization

          -  Pregnant or lactating patients, or fertile female patients with a positive pregnancy
             test, or fertile female patients unwilling to use adequate contraception during
             treatment and 30 days after completion of treatment

          -  Sexually active male patients unwilling to practice contraception while participating
             on the study and up to 30 days after completion of treatment

          -  Legal incapacity or limited legal capacity, unless authorization is granted by a legal
             guardian
Clinical trial NCT00569192 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: 0.135mg map0010, 0.25mg map0010, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female asthmatic children with mild to moderate persistent asthma.

          -  12 months to 8 years of age.

          -  For children age 4 to 8 years: Documented diagnosis of asthma at least 3 months prior
             to Visit 1, per NIH (EPR-3) criteria.

          -  For infants age 12 to <48 months old: 2 or more wheezing episodes in past 12 months
             which lasted > 1 day and affected sleep.

          -  AND with at least one major or two minor risk factors.

        Exclusion Criteria:

          -  Any other significant childhood illness/abnormality or chronic lung disease

          -  Any history of upper or lower respiratory tract infection, within 2 weeks of
             screening.

          -  Any history of acute or severe asthma attack requiring ICU admission or ventilatory
             support.

          -  Use of any corticosteroid, including inhaled, parental, intranasal, or topical
             corticosteroid within 2 weeks of screening.

          -  Any use of oral corticosteroids within 30 days of screening or prolonged use (>10
             consecutive days) of oral corticosteroids, within 12 weeks of screening.
Clinical trial NCT00352664 (phase 3, status: terminated)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: donepezil, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low patient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patient with drowsiness/sedation caused by opiate for > 3 days and its intensity more
             or equal to 3/10 (0 to 10 scale; 0 = no sedation, 10=worst possible sedation).

          2. Patient receiving a regular dose of a strong opioid for the treatment of cancer pain,
             and no dose changes or dose change within 50% for at least 48 hours.Regular
             administration, defined as short acting opioids oral or parenteral every 4 hours
             around clock, slow release oral opioids every 12 hs or 24 hs, or transdermal opioids
             every 72 hours. Strong opioids include morphine, hydromorphone, methadone, fentanyl,
             and oxycodone.

          3. Patient with relatively intact cognition defined by the Mini Mental State Examination
             according to age and educational level. A score of 24 or above is usually considered
             normal.

          4. Patient willing to engage in follow up visit with a nurse by phone on day 2-7 (each
             day), 11 and 15 of the study and to return for follow up visit on day 8 of treatment.
             If patient is unable to come to clinic, assessment will be performed through
             telephone.

          5. Sexually active females at risk of being pregnant with a negative urine pregnancy test

          6. Written consent form signed.

          7. Patients are 18 years or older

          8. Concurrent radiation treatment (defined as 10 or less fractions for a palliative
             indication) is allowed

          9. Concurrent chemotherapy is allowed, if the first two cycles have been well tolerated
             (defined as no grade 3 or 4 non-hematological toxicity)

        Exclusion Criteria:

          1. Major contraindication to donepezil i.e. hypersensitivity to donepezil or piperidine
             derivatives.

          2. Patients in whom a major change in opiate dose, analgesia requirements, anesthetic
             procedures or general anesthetic is expected over the next seven days.

          3. Treatment with anti-cholinergic agents (i.e., glycopyrrolate)

          4. Patients taking Methylphenidate.

          5. Patients with tube feeding (due to difficulty of accurate assessing some of the
             symptoms such as appetite and anorexia).

          6. History of ongoing arrhythmia causing a rhythm other than a sinus rhythm
Clinical trial NCT01120717 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: qva149, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 yrs

          -  Smoking history of at least 10 pack years

          -  Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)

          -  Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and
             post-bronchodilator FEV1/FVC (forced vital capacity) <70%

        Exclusion Criteria:

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for inhaled anticholinergic agents and β2 agonists

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00285376 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vilazodone
SMILES: NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients 18-65 years of age, inclusive.

          -  A diagnosis of MDD, single episode or recurrent, according to DSM-IV-TR (296.2/296.3)
             with a current Major Depressive Episode of less than two year's duration with a
             minimum duration of at least 4 weeks.

          -  HAM-D score ≥ 22.

          -  HAM-D item 1 (depressed mood) score ≥ 2.

          -  Patients must be able to provide written informed consent to participate before
             beginning any trial related activities.

          -  Patients must be able to speak, read and understand English and possess the ability to
             respond to questions and follow simple instructions.

        Exclusion Criteria:

          -  A current (or within 6 months prior to the Screening Visit) Axis I disorder of Post
             Traumatic Stress Disorder, Eating Disorder, Obsessive Compulsive Disorder (Generalized
             Anxiety Disorder, Social Phobia or Simple Phobia will be allowed).

          -  A history of schizophrenia, schizoaffective disorder or bipolar I or II disorder (with
             a history of hypomanic or manic episodes).

          -  DSM-IV-TR criteria for substance abuse (alcohol or drugs) within 3 months prior to
             Screening Visit or substance dependence within 6 months prior to the Screening Visit.

          -  Criteria for any of the following DSM-IV-TR MDD Specifiers: [a] With Catatonic
             Features; [b] With Postpartum Onset; [c] With Seasonal Pattern.
Clinical trial NCT01370538 (phase 3, status: completed)
Conditions: heartburn
ICD codes: R12
Drugs: esomeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and non-pregnant ,non-lactating females 18 years or older

          -  Experience heartburn at least 2 days a week

          -  Having heartburn that has responded to heartburn medication

          -  Must discontinue any current heartburn medications

        Exclusion Criteria:

          -  Having a history of erosive esophagitis verified by endoscopy

          -  Having a history of GERD which was diagnosed by a physician

          -  Inability to take study medication or complete the study and all study procedures

          -  Subjects that have required more than one 14-day course of PPI treatment within the
             past 4 months
Clinical trial NCT00396214 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: bifeprunox, quetiapine, bifeprunox
SMILES: O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1
Reason stopped: 
    this trial discontinued on 2 may 2008 due to lack of enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Schizophrenia

          -  18-65 years

          -  No hospitalization for an exacerbation of schizophrenia within two months prior to
             screening and during the screening period

        Exclusion Criteria:

          -  Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric
             diagnosis other than schizophrenia

          -  At significant risk of suicide, and the potential for violent behavior (likely to harm
             themselves or others) based on history
Clinical trial NCT00486434 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: smc021 oral calcitonin, smc021 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Medical history and symptoms of knee osteoarthritis

        Exclusion Criteria:

          -  Any other disease or medication affecting the bone or cartilage.

          -  Any clinical signs or laboratory evidence diseases, which in the Investigator's
             opinion would preclude the participant from adhering to the Protocol or completing the
             trial.

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT02560974 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants greater than or equal to (>=) 18 years of age

          -  Gastric adenocarcinoma, Stage II, IIIa or IIIb

          -  Potentially curative resection of tumor within 6 weeks prior to randomization

          -  Previously untreated with chemotherapy or radiotherapy

        Exclusion Criteria:

          -  Serious concomitant medical illnesses that would limit life expectancy to less than
             (<) 5 years

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study

          -  Any evidence of metastatic disease (including presence of tumor cells in the ascites)
Clinical trial NCT00457002 (phase 3, status: completed)
Conditions: venous thrombosis, pulmonary embolism
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: apixaban, enoxaparin
SMILES: COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  men and non-pregnant, non-breastfeeding women

          -  40 years or older

          -  hospitalized with congestive heart failure or acute respiratory failure

          -  infection (without septic shock)

          -  acute rheumatic disorder

          -  inflammatory bowel disease

        Exclusion Criteria:

          -  patients with venous thromboembolism (VTE)

          -  active bleeding or at high risk of bleeding

          -  unable to take oral medication

          -  with diseases requiring ongoing treatment with anticoagulants or antiplatelets other
             than aspirin at a dose ≤ 165 mg/day.
Clinical trial NCT01763918 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Diagnosis of heterozygous familial hypercholesterolemia

          -  On a stable dose of an approved statin and lipid regulating medication

          -  Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L)

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

        Exclusion Criteria:

          -  Homozygous familial hypercholesterolemia

          -  LDL or plasma apheresis

          -  New York Heart Association (NYHA) III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes, poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
Clinical trial NCT00360087 (phase 3, status: terminated)
Conditions: pulmonary hypertension, sickle cell anemia
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: bosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        -  INCLUSION CRITERIA

          -  Completion of the 16-week treatment period in the double-blind ASSET study

          -  Women of childbearing potential must have a negative result on their serum pregnancy
             test and use reliable methods of contraception during study treatment and for 3 months
             after study treatment termination.

        Reliable methods of contraception are:

          1. Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in
             combination with a spermicide.

          2. Intra-uterine devices.

          3. Oral, injectable, transdermal or implantable contraceptives only in combination with a
             barrier method.

        Hormone-based contraceptives alone, regardless of the route of administration, are not
        considered to be reliable methods of contraception.

        Abstention, rhythm method, and contraception by the partner alone are not acceptable
        methods of contraception.

        Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e.,
        amenorrhea for at least 1 year), or surgically or naturally sterile.

        Signed written informed consent is obtained from the patient or patient's parent/ legal
        representative prior to initiation of any study-related procedure.

        EXCLUSION CRITERIA

        All patients (Groups A and B):

          1. Any major protocol violation in the preceding double-blind ASSET study*.

          2. Hemoglobin concentration less than 6.0 g/dL.

          3. Pregnancy or breast-feeding.

             * Protocol violations will be reviewed by the monitor during site visits and discussed
             with the study staff on an ongoing basis and at the patient's completion of the
             double-blind study.

             Group B only:

          4. Acute liver disease.

          5. Newly diagnosed cirrhosis or portal hypertension.

          6. ALT greater than or equal to 3 times ULN and/or albumin greater than 20% below LLN.

          7. Newly diagnosed psychotic, addictive or other disorder limiting the ability to provide
             informed consent or to comply with study requirements.
Clinical trial NCT00439777 (phase 3, status: completed)
Conditions: pulmonary embolism
ICD codes: I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: rivaroxaban (xarelto, bay59-7939), enoxaparin overlapping with and followed by vka
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed acute symptomatic proximal PE with or without symptomatic DVT

        Exclusion Criteria:

          -  Legal lower age limitations (country specific)

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current episode of DVT and/or PE

          -  Other indication for VKA than DVT and/or PE

          -  The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from
             36 hours to a maximum of 48 hours.